Quick Answer
First-trimester screening for chromosomal abnormalities is optimally performed between 11+0 and 13+6 weeks of gestation. The combined screening test — NT measurement plus maternal serum free β-hCG and PAPP-A — achieves detection rates of approximately 85–90% for Down syndrome (Trisomy 21) at a 5% false-positive rate when performed within this window. NIPT (Non-Invasive Prenatal Testing) can be offered from 10 weeks onwards and carries a higher sensitivity, but does not replace diagnostic confirmation in screen-positive cases. This article covers the timing rationale, measurement standards, counselling framework, and the specific considerations that apply in Indian practice.
First-trimester screening is one of the most clinically consequential steps in antenatal care — and one of the areas where clinical practice among OBGYN doctors varies most. Timing errors, suboptimal NT measurement technique, incomplete counselling, and inconsistent integration of combined screening markers are all common in routine practice, and all affect the clinical utility of the screening result.
This article is a protocol-level reference. It covers the timing window and why it matters, the components of combined screening, NT measurement standards, the role of NIPT, second-line biochemical markers, and the counselling framework a practising clinician needs when delivering a screen-positive result. It also addresses the specific legal and procedural context that applies to prenatal diagnosis in India.
Doctors who want structured training in prenatal screening interpretation and fetal ultrasound can explore MGA’s Fellowship in Fetal Medicine, which covers this content in depth across dedicated modules.
What this article covers
- Why the 11–14 week window matters — the biological rationale
- NT measurement — standards and common errors
- Combined first-trimester screening — components and interpretation
- NIPT — role, timing, and limitations in Indian practice
- Second-trimester integration — when to offer the quadruple test
- Screen-positive results — the counselling framework
- PCPNDT context — what practitioners need to know
- Frequently asked questions
Why the 11–14 week window matters — the biological rationale
The 11+0 to 13+6 week window is not arbitrary. Nuchal translucency — the fluid-filled space at the back of the fetal neck, measured on ultrasound — reaches its maximum diagnostic utility within this window. NT is physiologically present in all fetuses to a small degree, and naturally increases after 14 weeks in unaffected pregnancies as lymphatic drainage establishes. Outside this window, NT measurements are either technically not yet feasible (before 11 weeks, the fetus is too small for reliable measurement) or diagnostically unreliable (after 14 weeks, NT has already begun to resolve in normal fetuses, narrowing the gap between affected and unaffected).
The CRL (crown-rump length) range within this gestational window is 45–84 mm. The CRL measurement determines whether the fetus is within the NT measurement window, not gestational age alone — this distinction matters when dates are uncertain.
Practical point: When a patient presents at or near 14 weeks, do not delay referral to a better-equipped centre if your local equipment or training is not adequate for NT measurement. A NT measurement at 13+5 is still within protocol; a measurement at 14+1 is not. Missing the window means the combined test cannot be performed and the patient defaults to second-trimester screening alone, which has lower sensitivity.
NT measurement — standards and common errors
NT measurement is the most skill-dependent component of first-trimester screening. Poorly performed NT measurements produce unreliable risk calculations regardless of how good the serum marker results are.
Measurement standards (FMF protocol)
The Fetal Medicine Foundation (FMF) protocol is the widely used international standard. Key requirements:
- Fetal position: Sagittal section of the fetus in a neutral position — neither hyperflexed nor hyperextended. Both hyperflexion and hyperextension artificially alter the NT measurement.
- Image magnification: The fetal head and upper thorax should occupy the full screen. The fetus should fill at least 75% of the screen.
- Calipers: Placed on the inner borders of the nuchal space — not on the skin lines themselves. The horizontal part of the caliper should be barely visible against the echogenic line.
- Skin line vs amnion: The amniotic membrane must not be confused with the skin line. Wait for the fetus to move away from the amnion if they appear fused.
- Multiple measurements: Take at least three measurements and use the largest for risk calculation.
Common measurement errors
| Error | Effect on Measurement | Correction |
|---|---|---|
| Neck hyperflexion | Falsely increases NT by up to 0.6 mm | Reposition, wait for neutral posture |
| Measuring on amnion, not skin | Falsely increases NT | Wait for fetal movement to separate amnion |
| Calipers on outer borders | Overestimates NT | Use inner-to-inner caliper placement |
| Insufficient magnification | Imprecise caliper placement | Head and thorax to fill >75% of screen |
| Single measurement accepted | Misses higher reproducible value | Minimum 3 measurements; use the largest |
Combined first-trimester screening — components and interpretation
Combined screening integrates three inputs into a single risk calculation for chromosomal abnormalities, primarily Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
Three components
1. Maternal age-related background risk: The prior probability of chromosomal abnormality based on the mother’s age at the expected date of delivery — the starting point before any test modifies it.
2. Nuchal translucency (NT) measurement: Expressed as a multiple of the median (MoM) for that gestational age and CRL. An NT at or above the 95th centile (approximately ≥2.5 mm at 11 weeks, ≥3.5 mm at 13 weeks) raises the posterior risk substantially, though the precise risk change depends on the full calculation.
3. Maternal serum markers — free β-hCG and PAPP-A: Free β-hCG is elevated in Down syndrome pregnancies at 11–13 weeks (approximately 2.0 MoM). PAPP-A is reduced in Down syndrome pregnancies at 11–13 weeks (approximately 0.4–0.5 MoM). These two markers change in opposite directions in Trisomy 21, which is what gives the combined test its discriminatory power.
Risk threshold and result interpretation
The standard combined screening risk threshold for classifying a result as screen-positive is 1 in 300 (or 1:300) for Trisomy 21. Results above this threshold (e.g., 1:50, 1:120) are screen-positive; results below (e.g., 1:1500) are screen-negative. This threshold is a probability cut-off, not a diagnosis — a 1:50 risk does not mean the baby has Down syndrome; it means the statistical risk in this pregnancy is 2%, compared to the population background.
Performance characteristics of combined screening:
At a 5% false-positive rate: Detection rate for Trisomy 21 approximately 85–90%. Detection rate for Trisomy 18 approximately 90–95%. Detection rate for Trisomy 13 approximately 90%. These figures are from published literature and reflect performance under protocol-compliant conditions with quality-assured NT measurement.
NIPT — role, timing, and limitations in Indian practice
Cell-free DNA testing (NIPT — Non-Invasive Prenatal Testing) analyses fragments of placental DNA in maternal blood to screen for chromosomal abnormalities. It can be performed from 10 weeks of gestation onwards.
Performance compared to combined screening
For Trisomy 21, NIPT carries a sensitivity above 99% with a false-positive rate of approximately 0.1% — substantially better than combined screening. For sex chromosome aneuploidies (Turner syndrome, Klinefelter syndrome), NIPT performs well but with slightly lower positive predictive value. For microdeletions, the evidence is more limited and varies by laboratory.
Where NIPT sits in the pathway
NIPT is a screening test, not a diagnostic test. A positive NIPT result requires confirmation by diagnostic amniocentesis or CVS before clinical action is taken. This is a critical counselling point that is frequently under-communicated to patients — a positive NIPT is not equivalent to a confirmed diagnosis.
NIPT can be offered as:
- Primary screening (contingent model) — all patients offered NIPT as first-line
- Contingent screening — NIPT offered only to patients with intermediate risk on combined screening (typically 1:51 to 1:1000)
- Second-line after positive combined screen — NIPT offered as an alternative to immediate invasive testing for patients with screen-positive combined results who want additional information before deciding on amniocentesis
Cost considerations in Indian practice
NIPT remains significantly more expensive than combined screening in the Indian market. Combined screening (NT ultrasound plus serum markers) is more widely accessible, particularly outside metro cities. For patients in whom cost is prohibitive, combined screening remains a clinically appropriate and evidence-based first-line option — the cost-benefit discussion is a genuine counselling component, not a compromise.
Second-trimester integration — when to offer the quadruple test
The quadruple test (AFP, total hCG, uE3, inhibin A) is the standard second-trimester biochemical screening option, offered between 15 and 20 weeks. It is relevant in three specific situations in current practice:
- Missed first-trimester window: Patients who present after 14 weeks cannot have combined screening. The quadruple test is the appropriate alternative.
- Integrated screening: First-trimester NT plus serum markers combined with second-trimester markers in a single integrated risk calculation — produces higher detection rates than either trimester alone but requires that results are withheld until the second trimester result is available.
- Neural tube defect screening: AFP as part of the second-trimester panel is the primary biochemical marker for open neural tube defects. First-trimester combined screening does not screen for NTDs — the 18–20 week anomaly scan and/or second-trimester AFP are the relevant screening tools.
Screen-positive results — the counselling framework
How a screen-positive result is communicated determines whether the patient understands their actual risk and makes an informed decision about next steps — or leaves the consultation confused, unnecessarily distressed, or making a decision without full information. The counselling encounter at this stage has a clear structure.
What to establish first
Before discussing options, confirm the patient understands what a screening result means: a screen-positive result is a probability, not a diagnosis. A 1:50 risk means 1 in 50 pregnancies with this result will have Trisomy 21 — which also means 49 in 50 will not. Anchoring this understanding prevents premature distress and frames the next decision clearly.
The decision framework after a screen-positive result
| Option | What It Provides | Key Consideration |
|---|---|---|
| Proceed to amniocentesis or CVS | Diagnostic certainty — karyotype or chromosomal microarray | Procedural risk of pregnancy loss approximately 0.5–1%; timing — CVS 11–14 weeks, amniocentesis from 15 weeks |
| Intermediate step: NIPT | High-sensitivity re-screen without procedural risk | Still a screening test; a positive NIPT still requires invasive confirmation before clinical decision |
| Detailed anomaly scan at 18–20 weeks | Structural assessment for soft markers and major anomalies | Does not provide karyotype; cannot rule out chromosomal abnormality; may modify risk estimate |
| Continue pregnancy without further investigation | Patient’s informed choice to proceed without diagnostic confirmation | Fully valid patient choice; document clearly; ensure patient understands residual risk |
Counselling principles
Non-directiveness is the standard — the clinician’s role is to provide accurate information, not to steer the decision. The patient’s values, beliefs, and personal circumstances determine the right choice, not a generic risk threshold. Document the counselling discussion, the options presented, and the decision made.
PCPNDT context — what practitioners need to know
The Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act governs the use of ultrasound and prenatal diagnostic procedures in India with the specific intent of preventing sex selection. Practitioners performing first-trimester screening must be familiar with their obligations under this Act.
Key practical points for clinicians:
- Registration: All ultrasound machines used for obstetric scanning must be registered under the PCPNDT Act. Clinics and diagnostic centres must be registered and renewed periodically.
- Form F: Every obstetric ultrasound requires completion of Form F — including the indication, referring doctor’s details, and patient’s written consent.
- Non-disclosure of sex: Sex determination and communication of fetal sex to the patient or family is prohibited under the Act at any gestational age. This applies equally to diagnostic procedures including CVS, amniocentesis, and NIPT when sex chromosome results are reported.
- Record retention: All Form F records must be maintained and are subject to inspection by appropriate authorities.
The PCPNDT framework exists to prevent sex determination misuse. When counselling patients on NIPT — which provides chromosomal information including sex chromosomes — practitioners should be aware that sex chromosome results require careful handling. Standard practice in India is to report sex chromosome aneuploidies (Turner, Klinefelter) as clinically relevant findings while ensuring that fetal sex disclosure does not occur in the context of NIPT reporting. Labs offering NIPT should have clear policies on this — clarify before ordering if uncertain.
Build structured expertise in prenatal screening and fetal medicine
MGA’s Fellowship in Fetal Medicine · 17 modules · CPD accredited · 12 months online
Related articles and programs
Frequently asked questions
What is the correct timing for first-trimester screening?
Combined first-trimester screening should be performed between 11+0 and 13+6 weeks of gestation, corresponding to a fetal CRL of 45–84 mm. This window allows NT measurement at its most diagnostically reliable period. Screening before 11 weeks is technically not feasible due to fetal size; after 14 weeks the NT has begun to resolve and the measurement is no longer valid for combined screening risk calculation.
What is the combined first-trimester screening test?
Combined screening integrates three inputs: maternal age-related background risk, nuchal translucency (NT) measurement on ultrasound, and two maternal serum markers — free β-hCG (elevated in Trisomy 21) and PAPP-A (reduced in Trisomy 21) — into a single posterior risk calculation. At a 5% false-positive rate, it achieves detection rates of approximately 85–90% for Trisomy 21.
How is the NT scan different from the dual marker test?
The NT scan is an ultrasound measurement of the nuchal translucency space. The dual marker test refers to the two maternal serum markers — free β-hCG and PAPP-A — drawn in the first trimester. Together, these three components (NT + dual markers + maternal age) constitute the combined first-trimester screening test. The dual marker test alone (without NT) is less accurate than combined screening.
Is NIPT better than combined screening?
NIPT has higher sensitivity for Trisomy 21 (above 99%) and a lower false-positive rate (approximately 0.1%) compared to combined screening. However, NIPT is a screening test — a positive result still requires diagnostic confirmation by amniocentesis or CVS. In Indian practice, NIPT is significantly more expensive than combined screening and less universally accessible, which influences the choice for many patients.
What should I do with a screen-positive combined test result?
A screen-positive result (typically defined as a Trisomy 21 risk of 1:300 or higher) means the calculated risk in this pregnancy is above the threshold — it does not mean the baby has Trisomy 21. The standard options are: proceed to diagnostic amniocentesis or CVS for karyotype confirmation; opt for NIPT as an intermediate high-sensitivity screen; have a detailed anomaly scan; or continue the pregnancy without further investigation. All options are valid — counselling should present them non-directively.
What does PCPNDT require for first-trimester ultrasound?
All obstetric ultrasound scans in India must be performed on a registered machine at a registered facility. Every scan requires completion of Form F, including the patient’s written consent and the scan indication. Fetal sex disclosure is prohibited under the Act. Form F records must be retained and are subject to inspection. Any doctor performing first-trimester screening should ensure their facility is registered and their record-keeping is current.
Medical Global Academy — Editorial Team
This article is produced for educational purposes by MGA’s academic team. It provides a clinical protocol reference for practising OBGYN doctors and does not replace institutional protocols, national guidelines, or regulatory requirements under PCPNDT. Practitioners should follow the guidelines of the Fetal Medicine Foundation, FOGSI, and the Ministry of Health as applicable to their practice context. Last reviewed: August 2026.